A phase 2a, open-label, non-randomized, 2-part multicenter, combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs S 81694 (Primary) ; Atezolizumab; Decitabine
- Indications Liver cancer
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 07 Jan 2025 According to a Nerviano Medical Sciences media release, company announces launch of new clinical trial NMS-153 in Combination with Atezolizumab and clinical trial agreement with Roche and Roche is the collaborator of this trial.